Abstract
Amyloid plaque is associated with several neuronal and non-neuronal degenerative diseases. More than twenty human proteins can fold abnormally to form pathological deposits like amyloid plaque. Strategies for treating such diseases include therapies designed to decrease protein plaque formation or its complete clearance, but monitoring/clinical trials of these treatments are limited by the lack of effective methods to monitor amyloid deposits in the organs/tissues of living patients. The current study shows binding and staining ability of quinacrine to protein amyloid deposits, using Hen Egg White Lysozyme (HEWL) as model system and characterization of its binding interaction with HEWL, employing several biophysical techniques. Since quinacrine can pass the blood brain barrier, the current report suggests potential application of quinacrine for antemortem diagnostic of amyloid.
Keywords: Amyloid plaque, fluorescence quenching, FTIR, hen egg white lysozyme, imaging, quinacrine, fibrillar protein, Alzheimer’s disease, Parkinson’s Disease, Type II Diabetes Mellitus
Protein & Peptide Letters
Title:Evaluating Quinacrine as a Potential Amyloid Imaging Compound: Studies on Hen Egg White Lysozyme as Model System
Volume: 19 Issue: 8
Author(s): Manjeet Kumar, Nandini Sarkar and Vikash Kumar Dubey
Affiliation:
Keywords: Amyloid plaque, fluorescence quenching, FTIR, hen egg white lysozyme, imaging, quinacrine, fibrillar protein, Alzheimer’s disease, Parkinson’s Disease, Type II Diabetes Mellitus
Abstract: Amyloid plaque is associated with several neuronal and non-neuronal degenerative diseases. More than twenty human proteins can fold abnormally to form pathological deposits like amyloid plaque. Strategies for treating such diseases include therapies designed to decrease protein plaque formation or its complete clearance, but monitoring/clinical trials of these treatments are limited by the lack of effective methods to monitor amyloid deposits in the organs/tissues of living patients. The current study shows binding and staining ability of quinacrine to protein amyloid deposits, using Hen Egg White Lysozyme (HEWL) as model system and characterization of its binding interaction with HEWL, employing several biophysical techniques. Since quinacrine can pass the blood brain barrier, the current report suggests potential application of quinacrine for antemortem diagnostic of amyloid.
Export Options
About this article
Cite this article as:
Kumar Manjeet, Sarkar Nandini and Kumar Dubey Vikash, Evaluating Quinacrine as a Potential Amyloid Imaging Compound: Studies on Hen Egg White Lysozyme as Model System, Protein & Peptide Letters 2012; 19 (8) . https://dx.doi.org/10.2174/092986612801619598
DOI https://dx.doi.org/10.2174/092986612801619598 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiac Biomarkers in the Identification of Future Risk in Chronic Obstructive Pulmonary Disease
Current Topics in Medicinal Chemistry DGAT: Novel Therapeutic Target for Obesity and Type 2 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Carotid Intima Media-thickness and Genes Involved in Lipid Metabolism in Diabetic Patients using Statins – a Pathway Toward Personalized Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Perfusion-diffusion Mismatch Predicts Early Neurological Deterioration in Anterior Circulation Infarction without Thrombolysis
Current Neurovascular Research Mechanisms Underlying Beneficial Health Effects of Tea Catechins to Improve Insulin Resistance and Endothelial Dysfunction
Endocrine, Metabolic & Immune Disorders - Drug Targets Can the Electrophysiological Action of Rosiglitazone Explain its Cardiac Side Effects?
Current Medicinal Chemistry Therapeutic Proteins for Treatment of Corneal Epithelial Defects
Current Medicinal Chemistry Oral L-Carnitine: Metabolite Formation and Hemodialysis
Current Drug Metabolism Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile
Current Cancer Drug Targets Physical Function and Exercise in Older Patients with Cardiovascular and Respiratory Conditions
Current Pharmaceutical Design Editorial [ Diseases of the Kidney: Molecular Mechanisms and Current Therapy Executive Editor: Stephen I-Hong Hsu ]
Current Molecular Medicine Amyloidogenicity and Aggregate Cytotoxicity of Human Glucagon-Like Peptide-1 (hGLP-1)
Protein & Peptide Letters Perioperative Glycemic Management in Insulin Pump Patients Undergoing Noncardiac Surgery
Current Pharmaceutical Design The Quest for Novel Biomarkers in Early Diagnosis of Diabetic Neuropathy
Current Proteomics Is there U-turn from Insulin Back to Pills in Diabetes?
Current Vascular Pharmacology Lipid-Based Systems for Delivery of Biological Macromolecules
Recent Patents on Nanomedicine Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Identifying Risk Factors for Clinically Significant Diabetic Macula Edema in Patients with Type 2 Diabetes Mellitus
Current Diabetes Reviews Glucose Transport Regulators
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents